=> D HIS

(FILE 'HOME' ENTERED AT 15:30:35 ON 13 SEP 2001)

FILE 'CROPU, DGENE, DPCI, ENCOMPPAT, ENCOMPPAT2, EUROPATFULL, HCAOLD, HCAPLUS, IFIPAT, INPADOC, JAPIO, PAPERCHEM2, PATDD, PATDPA, PATOSDE, PATOSEP, PATOSWO, PCTFULL, PIRA, RAPRA, SYNTHLINE, TULSA, TULSA2, USPATFULL, WPIDS' ENTERED AT 15:31:11 ON 13 SEP 2001

L1 614 S (DRUG OR PHARMACEUTICAL) (L) BIFUNCT? (L) BIODISTRIBUT?
L2 611 DUP REM L1 (3 DUPLICATES REMOVED)
L3 153 S L2 AND DALTON
L4 123 S L3 AND PY<=1999
L5 116 S L4 AND TARGET?
L6 21 S L5 AND (5000 DALTON# OR 5,000 DALTON# OR 5 KDA OR 5 KILODAL

? d ibib ab 1 21

L6 ANSWER 1 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1999PC06951 PCTFULL
TITLE (ENGLISH): USE OF BI-SPECIFIC ANTIBODIES FOR IRE **TARGETING** DIAGNOSIS AND THERAPY
TITLE (FRENCH): UTILISATION D'ANTICORPS BI-SPECIFIQUES POUR DIAGNOSTIC ET THERAPIE DE PRE CIBLAGE
INVENTOR(S): HANSEN, Hans, J.; GRIFFITHS, Gary, L.; LEUNG, Shui-on; MOBILDE, William, J.; QU, Zhengqing
PATENT ASSIGNEE(S): IMMUNOMEDICS, INC.
LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9966951	**A2**	**19991229**

DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 1999-US13879 19990622
PRIORITY (ORIGINAL): US 1998-60/090142 19980622
US 1998-60/104156 19981014

ABEN The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a **targeted** tissue and at least one other arm that specifically binds a **targetable** conjugate. The **targetable** conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The **targetable** conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

ABFR L'invention concerne un anticorps bi-specifique ou un fragment d'anticorps pourvu d'au moins un bras qui se lie specifiquement a un tissu cible et d'un autre bras qui se lie specifiquement a un conjugue pouvant etre vise. Ce dernier comporte une partie vecteur qui comporte ou porte au moins un epitope reconnaissable par au moins un arbre dudit anticorps bi-specifique ou dudit fragment d'anticorps. Le conjugue pouvant etre vise comporte egalement un ou plusieurs agents ou enzymes therapeutiques ou diagnostiques. L'invention concerne egalement des produits de recombinaison et des methodes de production et d'utilisation de ces anticorps bi-specifiques et de ces fragments d'anticorps.

L7 ANSWER 2 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1999PC00367 PCTFULL
TITLE (ENGLISH): INTERNALIZING ErbB2 ANTIBODIES
TITLE (FRENCH): ANTICORPS ERBB2 D'INTERNALISATION
INVENTOR(S): MARKS, James, D.; POUL, Marie, Alix
PATENT ASSIGNEE(S): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
LANGUAGE OF PUBL.: English

LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9955367	**A1**	**19991104**

DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-US7395 19990423
PRIORITY (ORIGINAL): US 1998 60/082953 19980424
US 1999-09/250056 19990212

ABEN This invention provides novel erbB2-binding internalising antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.

ABFR L'invention porte sur de nouveaux anticorps d'internalisation liaison ERBB2. Les anticorps, appel s F5 et C1, se lient sp cifiquement l'antig ne c-erbB2 et, lors de la liaison, sont facilement internalis s dans la cellule supportant le marqueur c-erbB2. L'invention porte galement sur des mol cules chim res comprenant les anticorps F5 et/ou C1 li s une ou plusieurs mol cules effectrices.

L6 ANSWER 3 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1996004304 PCTFULL
TITLE (ENGLISH): FIBRIN-BINDING PEPTIDES, DNA CODING THEREFOR AND USES THEREOF
TITLE (FRENCH): PEPTIDES DE FIXANT A LA FIBRINE, A D N LES CODANT ET LEURS UTILISATIONS
INVENTOR(S): GOLD, Leslie, I.; ROSTAGNO, Agueda, A.
PATENT ASSIGNEE(S): NEW YORK UNIVERSITY
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9604304	**A1**	**19960215**

DESIGNATED STATES: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1995-US9819 19950801
PRIORITY (ORIGINAL): US 1994 8/285857 19940801

ABEN Fibrin-binding molecules are provided which include at least one peptide essentially corresponding to the 10F1.11F1 module pair of fibronectin and includes no more of the natural fibronectin molecule than the C-terminal 11kDa proteolytic fragment. Also disclosed are nucleic acid molecules encoding the fibrin-binding peptides, methods for making the peptides, methods for using the peptides in the diagnosis and treatment of cardiovascular, peripheral vascular, cerebrovascular, and other conditions associated with fibrin deposition, and assay methods for detecting a fibrin-binding molecule and for measuring fibrin.

ABF L'invention concerne des molecules se fixant a la fibrine et comprenant au moins un peptide correspondant essentiellement a la paire de modules 10 F1 11 F1 de fibronectine et ne comportant pas plus de molecule de fibronectine naturelle que de fragment proteolytique de

rabbit a terminaison C. Elle concerne également des molécules d'acide nucléique codant les peptides se fixant à la fibrine, des procédés de préparation desdits peptides, des procédés d'utilisation desdits peptides dans le diagnostic et le traitement de maladies cardio-vasculaires, vasculaires périphériques et cérébrovasculaires, ainsi que d'autres maladies provoquées par le dépôt de la fibrine, et enfin, des procédés d'analyse pour détecter une molécule se fixant à la fibrine et pour mesurer la fibrine.

L6 ANSWER 4 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1995031221 PCTFULL
TITLE (ENGLISH): SOMATOSTATIN BINDING PEPTIDE-METAL CHELATE CONJUGATES
TITLE (FRENCH): CONJUGUES PEPTIDE-CHELATE METALLIQUE SE LIANT A LA SOMATOSTATINE
INVENTOR(S): DEAN, Richard
PATENT ASSIGNEE(S): DIATECH, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9531221	**A1**	**19951123**

DESIGNATED STATES: AU CA CN JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1995-US6034 19950512
PRIORITY (ORIGINAL): US 1994-8/241625 19940512

ABEN This invention relates to diagnostic and radiodiagnostic agents, including radiolabeled scintigraphic imaging agents, and therapeutic and radiotherapeutic agents. The invention provides such agents and reagents for preparing such agents, and methods for producing and using such reagents. Specifically, the invention provides radiolabeled imaging agents and non-radioactively labeled imaging agents for imaging sites in a mammalian body and reagents for preparing these imaging agents. The invention also provides radiolabeled therapeutic agents, as well as non-radioactively labeled therapeutic agents, and reagents and methods for preparing these agents. The agents and reagents provided comprise a specific binding peptide, covalently linked to a metal ion-complexing moiety. Reagents, methods and kits for making such reagents, methods for labelling such reagents, and methods for using such labeled reagents are provided.

ABF La présente invention se rapporte à des agents diagnostiques et radiodiagnostiques, y compris des agents d'imagerie scintigraphiques radiomarqués, ainsi que des agents thérapeutiques et radiothérapeutiques. L'invention se rapporte à ces agents et à des réactifs servant à préparer ces agents, ainsi qu'à des procédés de production et d'utilisation de ces réactifs. L'invention se rapporte spécifiquement à des agents d'imagerie radiomarqués et à des agents d'imagerie marqués non radioactivement servant à former des images de sites du corps d'un mammifère, et à des réactifs permettant de préparer ces agents d'imagerie. L'invention se rapporte également à des agents thérapeutiques radiomarqués et à des agents thérapeutiques marqués non radioactivement, et à des réactifs et des procédés permettant de préparer ces agents. Les agents et le réactifs décrits comprennent un peptide de liaison spécifique, lié de manière covalente à une fraction de complexage d'ion métal. On décrit également des réactifs, des procédés et des kits permettant de préparer ces réactifs, des procédés de marquage de ces réactifs ainsi que des procédés d'utilisation de ces réactifs marqués.

L6 ANSWER 5 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1995029708 PCTFULL
TITLE (ENGLISH): TECHNETIUM-99m LABELED IMAGING AGENTS

TITLE (FRENCH): AGENTS D'IMAGERIE MARQUES AU TECHNETIUM 99m
INVENTOR(S): DEAN, Richard, T.; LISTER JAMES, John; McBRIDE, William
PATENT ASSIGNEE(S): DIATECH, INC.; DEAN, Richard, T.; LISTER JAMES, John; McBRIDE, William
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9529708	**A1**	**19951109**

DESIGNATED STATES: AU CA CN JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1995-US5340 19950501
PRIORITY (ORIGINAL): US 1994-8/236402 19940502

ABEN This invention relates to radiolabeled scintigraphic imaging agents and reagents for preparing such imaging agents and methods for producing and using such reagents. Specifically, the invention relates to reagents for preparing scintigraphic imaging agents for imaging sites in a mammalian body comprising a specific binding compound including specific-binding peptide embodiments thereof, covalently linked to a radiolabel complexing moiety. Reagents, methods and kits for making such reagents, and methods for using such reagents labeled with technetium-99m (Tc-99m) via Tc-99m complexing moieties comprising said reagents, are provided.

ABF Agents d'imagerie scintigraphique radiomarques et reactifs pour la preparation d'agents d'imagerie de ce type, et procedes de production et de mise en oeuvre de ces reactifs. Il s'agit plus precisement de reactifs pour la preparation d'agents d'imagerie scintigraphique destines a l'imagerie de certains sites dans le corps d'un mammifere, comportant un compose a liaison specifique, et, notamment, des formes peptidiques a liaison specifique de celui-ci, liees de maniere covalente a une fraction de complexion de radiomarqueurs. On a prevu des reactifs, des procedes et des trousses pour la fabrication de reactifs de ce type, et des procedes de mise en oeuvre de ces reactifs marques au technetium 99m (Tc-99m) par l'intermediaire de fractions de complexion de Tc 99m comportant ces reactifs.

L6 ANSWER 6 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1995015879 PCTFULL
TITLE (ENGLISH): PRETARGETING METHODS AND COMPOUNDS
TITLE (FRENCH): PROCEDES ET COMPOSES DE PRECIBLAGE
INVENTOR(S): THEODORE, Louis, J.; MEYER, Damon, L.; MALLETT, Robert, W.; KASINA, Sudhakar; RENO, John, M.; AYWORTHY, Donald, B.; GUSTAVSON, Linda, M.
PATENT ASSIGNEE(S): NEORX CORPORATION
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9515979	**A1**	**19950615**

DESIGNATED STATES: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1994-US14174 19941207
PRIORITY (ORIGINAL): US 1993-8/163183 19931207

ABEN Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed.

ABF L'invention concerne des procedes, des composes, des compositions et des kits presentant une efficacite pour l'administration preciblee d'agents diagnostiques et therapeutiques.

L6 ANSWER 7 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent

ACCESSION NUMBER: [illegible] PCTFULL
TITLE (ENGLISH): POLYMERIC CARRIERS FOR NON-COVALENT **DRUG** CONJUGATION
TITLE (FRENCH): VEHICULES POLYMERES POUR LA CONJUGAISON NON COVALENTE DE MEDICAMENTS
INVENTOR(S): GUSTAVSON, Linda, M.; ANDERSON, David, C.; MORGAN, Alton, C., Jr.
PATENT ASSIGNEE(S): NEORX CORPORATION
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9503064	**A1**	**19950202**

DESIGNATED STATES: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1994-US7734 19940712
PRIORITY (ORIGINAL): US 1993-8709515 19930726

ABEN Polymeric carriers are polypeptides comprising at least one **drug** binding domain that non-covalently binds a **drug**. A polymeric carrier may be attached to an ant body specific for desired **target** cells to form immunoconjugates that deliver a **drug** to the **target** cells in vivo. A polymeric carrier may be attached to a proteinaceous or a non proteinaceous ligand or anti-ligand to form a conjugate useful in pretargeting protocols to deliver a **drug** to **target** cells in vivo. The carriers are derived from **drug** binding proteins and produced through peptide synthesis or recombinant DNA technology.

ABF Des vehicules polymeres sont composes de polypeptides comprenant au moins un domaine de liaison de medicament presentant une liaison non covalente par rapport a un medicament. Un vehicule polymere peut etre fixe a un anticorps specifique contre des cellules cibles donnees pour former des immunoconjugues qui apportent un medicament in vivo aux cellules cibles. Un vehicule polymere peut etre fixe a un ligand ou anti-ligand proteinique ou non-proteinique afin de former un conjugue apte a etre utilise dans des protocoles de pre-ciblage pour apporter un medicament in vivo a des cellules cibles. Ces vehicules sont derives de proteines de liaison de medicaments et produits par la synthese de peptides ou la technologie de recombinaison d'ADN.

L6 ANSWER 8 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1994014976 PCTFULL
TITLE (ENGLISH): IMMUNE RESPONSE MODULATOR COMPLEX, AND USES THEREOF
TITLE (FRENCH): COMPLEXE MODULATEUR DE LA REPONSE IMMUNITAIRE, ET SES UTILISATIONS
INVENTOR(S): PIZZO, Salvatore, V.; CHU, Charleen, T.; OURY, Tim, D.
PATENT ASSIGNEE(S): DUKE UNIVERSITY; PIZZO, Salvatore, V.; CHU, Charleen, T.; OURY, Tim, D.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9414976	**A1**	**19940707**

DESIGNATED STATES: AU BB BG BR BY CA CZ FI HU JP KP KR KZ LK MG MW NO NZ PL RO RU SD SK UA AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

APPLICATION INFO.: WO 1993- [illegible] 19930107
PRIORITY (ORIGINAL.): US 1992- [illegible] 19921223

ABEN A method of enhancing antigen presentation is disclosed, wherein an antigen is modified by coupling or incorporation with alpha2 macroglobulin (alpha2M), a construct thereof, or a reactive fragment thereof. The antigen so prepared is capable of eliciting enhanced immune response from silent, scarce or weak epitopes. This may comprise an actual activation process, a shift in the dominance to a different epitope by reducing recognition of an immunodominant epitope, or another mechanism. Also included are the antibodies which recognize these epitopes, methods of treatment and use, including the preparation of monovalent and polyvalent vaccines, recombinant alpha2M constructs, and assay techniques and kits for performing such methods.

ABF Est decrit un procede pour stimuler la presentation de l'antigene, dans lequel un antigene est modifie par incorporation ou couplage avec une alpha2 macroglobuline (alpha2M), son produit de recombinaison, ou bien son fragment reactif. L'antigene ainsi prepare est capable de declencher une reponse immunitaire amelioree de la part d'epitopes silencieux, rares ou faibles. Ceci peut consister en un processus d'activation reelle, un glissement de dominance en faveur d'un epitope different par diminution de la reconnaissance d'un epitope immunodominant, ou bien un autre mecanisme. Sont egalement decrits les anticorps qui reconnaissent ces epitopes, des procedes de traitement et d'utilisation, notamment la preparation de vaccins monovalents et polyvalents, de produits de recombinaison de alpha2M, ainsi que des techniques et des trousses de dosage pour mettre en oeuvre de tels procedes.

L6 ANSWER 9 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1993025240 PCTFULL
TITLE (ENGLISH): PRETARGETTING METHODS AND COMPOUNDS
TITLE (FRENCH): PROCEDES ET COMPOSES DE PRECIBLAGE
INVENTOR(S): AXWORTHY, Donald, B.; THEODORE, Louis, J.; GUSTAVSON, Linda, M.; RENO, John, M.
PATENT ASSIGNEE(S): NEORX CORPORATION; AXWORTHY, Donald, B.; THEODORE, Louis, J.; GUSTAVSON, Linda, M.; RENO, John, M.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

	NUMBER	KIND	DATE
	WO 9325240	**A2**	**19931223**
DESIGNATED STATES:	CA JP US US AT BE CH IE DK ES FR GB GR IE IT LU MC NL PT SE		
APPLICATION INFO.:	WO 1993-US5406		19930607
PRIORITY (ORIGINAL):	US 1992-7/895588		19920609
	US 1992-7/995381		19921223
	US 1992-7/995383		19921223

ABEN Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti ligand **targeting** moiety conjugates, **target** cell retention enhancing moieties and additional methods are discussed.

ABF L'invention decrit des procedes, des composes, des compositions et des kits conçus pour la delivrance preciblee d'agents diagnostiques et therapeutiques. En particulier, elle decrit des procedes de marquage radiometallographique de la biotine et de radiohalogenation amelioree de la biotine, ainsi que des composes correspondants. Elle concerne egalement des agents d'elimination, des conjugues de fractions de

ciblage anti ligand, des fractions d'amplification de la retention de cellules ciblees, ainsi que des procedes correspondants.

L6 ANSWER 10 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1993027[illegible] PCTFULL
TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR ENHANCED **DRUG** DELIVERY
TITLE (FRENCH): COMPOSITIONS ET PROCEDES DESTINES A AMELIORER LA LIBERATION ET L'ACHEMINEMENT DE MEDICAMENTS
INVENTOR(S): HALE, Ron, L.; LU, Amy; SOLAS, Dennis; SELICK, Harold, E.; OLDENBURG, Kevin, R.; ZAFFARONI, Alejandro, C.
PATENT ASSIGNEE(S): AFFYMAX TECHNOLOGIES N.V.; HALE, Ron, L.; LU, Amy; SOLAS, Dennis; SELICK, Harold, E.; OLDENBURG, Kevin, R.; ZAFFARONI, Alejandro, C.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9325197	**A1**	**19931223**

DESIGNATED STATES: AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PT RO RU SD SE SK UA US US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1993-US5651 19930611
PRIORITY (ORIGINAL): US 1992-897219 19920612
US 1993-109463 19930127

ABEN The present invention relates to methods of delivering **pharmaceutical** agents across membranes, including the skin layer or mucosal membranes of a patient. A **pharmaceutical** agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.

ABF La presente invention se rapporte a des procedes de liberation d'acheminement d'agents pharmaceutiques a travers des membranes, y compris l'epiderme ou les muqueuses d'un patient. Un agent pharmaceutique est lie de maniere covalente a un modificateur chimique, via une liaison physiologiquement clivable, de telle facon que le transport et la liberation de l'agent par la membrane soient ameliores.

L6 ANSWER 11 OF 21 PCTFULL COPYRIGHT 2001 MicroPatent
ACCESSION NUMBER: 1992017216 PCTFULL
TITLE (ENGLISH): DELIVERY OF X RAY CONTRAST AGENTS USING RECEPTOR MEDIATED ENDOCYTOSIS
TITLE (FRENCH): ADMINISTRATION D'AGENTS DE CONTRASTE RADIOGRAPHIQUES A L'AIDE DE L'ENDOCYTOSE A MEDIATION PAR RECEPTEURS
INVENTOR(S): JOSEPHSON, Lee; JUNG, Chu; PALMACCI, Stephen
PATENT ASSIGNEE(S): ADVANCED MAGNETICS, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9217216	**A1**	**19921015**

DESIGNATED STATES: AT BE CA CH DE DK ES FR GB GR IT JP LU MC NL NO SE
APPLICATION INFO.: WO 1992-US2651 19920318
PRIORITY (ORIGINAL): US 1991-679527 19910402

ABEN The invention provides a method of **targeting** an x-ray contrast

agent to a specific population of cells or organ. **Targeting** may be accomplished by forming a complex of a radiopaque label with a saccharide capable of interacting with a cell receptor. The resulting complex may then be internalized into the specific population of cells or organ by receptor mediated endocytosis. In one embodiment of the invention, the radiopaque label may include a compound containing iodine and the saccharide may include arabinogalactan, galactan, or derivatives thereof. The invention provides a method for determining the metabolic viability or disease state of the **target** cells or organ by visualizing the extent, mode of uptake and excretion of the **targeted** x ray contrast agent by x-ray or computer tomography.

ABF Procede de ciblage sur un organe ou une population cellulaire specifique d'un agent de contraste radiographique. Le ciblage peut s'effectuer par formation d'un complexe d'un traceur opaque aux rayons X et d'un saccharide apte a cooperer avec un recepteur cellulaire. On peut ensuite incorporer le complexe ainsi obtenu a l'organe ou a la population cellulaire specifique au moyen d'une endocytose a mediation par recepteurs. Dans un mode de realisation, le traceur opaque aux rayons X peut comprendre un compose contenant de l'iode et le saccharide peut comprendre de l'arabinogalactane, du galactane ou des derives de ceux ci. On a egalement prevu un procede de determination de la viabilite metabolique ou de l'etat pathologique de l'organe ou des cellules cible par la visualisation par tomographie radiographique ou commandee par ordinateur de l'etendue, du mode de fixation et de l'excretion de l'agent de contraste radiographique cible.

L6 ANSWER 12 OF 21 USPATFULL

ACCESSION NUMBER:	1999:136685 USPATFULL
TITLE:	Pretargeting protocols for the enhanced localisation of cytotoxins to **target** sites and cytotoxic combinations useful therefore
INVENTOR(S):	Fritzberg, Alan R., Edmonds, WA, United States Abrams, Paul G., Seattle, WA, United States Reno, John M., Brier, WA, United States Axworthy, Donald B., Brier, WA, United States Graves, Scott S., Monroe, WA, United States Kasina, Sudhakar, Kirkland, WA, United States
PATENT ASSIGNEE(S):	NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5976535		19991102
APPLICATION INFO.:	US 1995-468513		19950606 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1993-163188, filed on 7 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. WO 1993-US5406, filed on 7 Jun 1993 which is a continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5288852

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Cunningham, Thomas M.
LEGAL REPRESENTATIVE:	Seed and Berry LLP
NUMBER OF CLAIMS:	3
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT:	4278

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for **targeting** cytotoxins to **target** sites by administration of a combination of conjugates are provided. Novel cytotoxic combinations for use in such methods are also provided.

L6 ANSWER 13 OF 21 USPATFULL

ACCESSION NUMBER: 1999:124443 USPATFULL

TITLE: In vivo binding pair pretargeting

INVENTOR(S): Pomato, Nicholas, Frederick, MD, United States
McCabe, Richard P., West Chester, PA, United States
Hawkins, Gregory A., Madison, WI, United States
Brodehorst, Reinhard, Hamburg, Germany, Federal Republic of
Kim, Chong Ho, Rockville, MD, United States
Vogel, Carl-Wilhelm, Hamburg, Germany, Federal Republic of

PATENT ASSIGNEE(S): PerImmune Holdings, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5965106		19991012
APPLICATION INFO.:	US 1995-461267		19950605 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-140186, filed on 4 Nov 1993, now patented, Pat. No. US 5578289 which is a continuation-in-part of Ser. No. US 1992-846453, filed on 4 Mar 1992, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Green, Lora M.
LEGAL REPRESENTATIVE: Gormley, Mary E.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 59 Drawing Figure(s); 42 Drawing Page(s)
LINE COUNT: 3967

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for in-vivo **targeting** a functional moiety in a patient by administering a **targeting** moiety coupled to an affinity component, wherein the **targeting** moiety has affinity for binding sites in a **target** area, and administering a binding partner to the affinity component coupled to a functional moiety to localise the functional moiety in the **target** area. Preferably the **targeting** moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.

L6 ANSWER 14 OF 21 USPATFULL

ACCESSION NUMBER: 1999:115890 USPATFULL

TITLE: Biotinidase resistant biotin-DOTA conjugates

INVENTOR(S): Axworthy, Donald B., Brier, WA, United States
Theodore, Louis J., Lynnwood, WA, United States
Gustavson, Linda M., Seattle, WA, United States
Reno, John M., Brier, WA, United States

PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5955605		19990921
APPLICATION INFO.:	US 1996-695940		19960812 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-351469, filed on 21 Feb		

1998, [illegible] Patent No. US [illegible]
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Eisenschenk, Frank C.
LEGAL REPRESENTATIVE: Reed and Berry LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 24 Drawing Page(s)
LINE COUNT: 4727
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Biotinidase-resistant biotin DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.

L6 ANSWER 15 OF 21 USPATFULL
ACCESSION NUMBER: 1998:95515 USPATFULL
TITLE: Fibrin binding peptide fragments of fibronectin
INVENTOR(S): Gold, Leslie I., New York, NY, United States
Rostagno, Agueda A., Elmhurst, NY, United States
Baron, Martin, Oxford, United Kingdom
Campbell, Iain D., Oxford, United Kingdom
Williams, Michael J., Oxford, United Kingdom
PATENT ASSIGNEE(S): New York University, New York, NY, United States (U.S. corporation)
Isis Innovation Ltd., Oxford, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5792742		19980811	<
APPLICATION INFO.:	US 1994 283857		19940801	(8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1991-714134, filed on 14 Jun 1991, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fitzgerald, David L.
LEGAL REPRESENTATIVE: Browdy and Neimark
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 57 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 4177
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Fibrin-binding molecules are provided which include at least one peptide essentially corresponding to one or both of the following portions of the natural fibronectin molecule. The first portion is that portion which includes the .sup.4 F1..sup.5 F1 module pair of fibronectin and includes no more of the natural fibronectin molecule than the N-terminal 25.9 kDa proteolytic fragment. The second portion includes the .sup.10 F1..sup.11 F1 module pair of fibronectin and includes no more of the natural fibronectin molecule than the C-terminal 11 kDa proteolytic fragment. Also disclosed are nucleic acid molecules encoding the fibrin-binding peptides, methods for making the peptides, methods for using the peptides in the diagnosis and treatment of cardiovascular, peripheral vascular, cerebrovascular, and other conditions associated with fibrin deposition, and assay methods for detecting a fibrin binding molecule and for measuring fibrin.

L6 ANSWER 16 OF 21 USPATFULL
ACCESSION NUMBER: 97:42628 USPATFULL
TITLE: Two step pretargeting methods using improved biotin active agent conjugates
INVENTOR(S): Reno, John M., Brier, WA, United States

Theodore, Louis J., Lynnwood, WA, United States
Gustavson, Linda M., Seattle, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5630996		19970520	
APPLICATION INFO.:	US 1993-122979		19930916	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned And Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342			

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Eisenschenk, Frank C.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 4768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti ligand-**targeting** moiety conjugates, **target** cell retention enhancing moieties and additional methods are discussed.

L6 ANSWER 17 OF 21 USPATFULL
ACCESSION NUMBER: 97:18284 USPATFULL
TITLE: Biotinidase resistant biotin-IOTA conjugates
INVENTOR(S): Axworthy, Donald B., Brier, WA, United States
Theodore, Louis J., Lynnwood, WA, United States
Gustavson, Linda M., Seattle, WA, United States
Reno, John M., Brier, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5608096		19970304	
	WO 9322240		19931223	
APPLICATION INFO.:	US 1995-351469		19950221	(8)
	WO 1993-US5406		19930607	
			19950221	PCT 371 date
			19950221	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-995383, filed on 23 Dec 1992, now abandoned And a continuation-in part of Ser. No. US 1992-995381, filed on 23 Dec 1992, now abandoned , each Ser. No. US which is a continuation in part of Ser. No. US 1992-895588, filed on 9 Jun 1992, now patented, Pat. No. US 5283342, issued on 1 Feb 1994
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Eisenschenk, Frank C.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 9

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: [illegible] Drawing Figure(s); [illegible] Drawing Sheet(s)
LINE COUNT: 4732
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Biotinidase resistant biotin DOTA conjugates, and methods of use thereof in diagnostic and therapeutic pretargeting methods are provided. These conjugates are useful in diagnosis and treatment of cancer.

L6 ANSWER 18 OF 21 USPATFULL
ACCESSION NUMBER: 97:17948 USPATFULL
TITLE: Compositions and methods for enhanced drug delivery
INVENTOR(S): Hale, Ron L., Woodside, CA, United States
Lu, Amy, Los Altos, CA, United States
Solas, Dennis, San Francisco, CA, United States
Selick, Harold E., Belmont, CA, United States
Oldenburg, Kevin R., Fremont, CA, United States
Zaffaroni, Alejandro C., Atherton, CA, United States
PATENT ASSIGNEE(S): Alkermes Technologies N.V., Middlesex, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5607691		19970304
APPLICATION INFO.:	US 1995-449185		19950524 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-164293, filed on 9 Dec 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-77236, filed on 14 Jun 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-898219, filed on 12 Jun 1992, now abandoned And a continuation-in-part of Ser. No. US 1993-9463, filed on 27 Jan 1993, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Levy, Neil S.
LEGAL REPRESENTATIVE: Stevens, Lauren L.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 5149
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of delivering pharmaceutical agents across membranes, including the skin layer or mucosal membranes of a patient. A pharmaceutical agent is covalently bonded to a chemical modifier, via a physiologically cleavable bond, such that the membrane transport and delivery of the agent is enhanced.

L6 ANSWER 19 OF 21 USPATFULL
ACCESSION NUMBER: 95:47701 USPATFULL
TITLE: Polymeric carriers for non-covalent drug conjugation
INVENTOR(S): Gustavson, Linda M., 19809 31st St., NE., Seattle, WA, United States 98155
Anderson, David C., 200 Lassen Dr., San Bruno, CA, United States 94066
Morgan, Jr., Alton C., 803 Driftwood Pl., Edmonds, WA, United States 98020

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5422105		19950530
APPLICATION INFO.:	US 1993-95515		19930726 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-248456, filed on 23 Sep 1988, now patented, Pat. No. US 5252713		

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Russel, Jeffrey E.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1625
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Polymeric carriers are polypeptides comprising at least one drug binding domain that non covalently binds a drug. A polymeric carrier may be attached to an antibody specific for desired **target** cells to form immunoconjugates that deliver a drug to the **target** cells in vivo. A polymeric carrier may be attached to a proteinaceous or a non-proteinaceous ligand or anti-ligand to form a conjugate useful in pretargeting protocols to deliver a drug to **target** cells in vivo. The carriers are derived from drug-binding proteins and produced through peptide synthesis or recombinant DNA technology.

L6 ANSWER 20 OF 21 USPATFULL
ACCESSION NUMBER: 93:85265 USPATFULL
TITLE: Polymeric carriers for non-covalent drug conjugation
INVENTOR(S): Morgan, Jr., Alton G., Edmonds, WA, United States
Anderson, David C., Seattle, WA, United States
PATENT ASSIGNEE(S): NeoRx Corporation, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5252713		19931012	<--
APPLICATION INFO.:	US 1988-213456		19880323 (7)	

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Russel, Jeffrey E.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1634
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Polymeric carriers are polypeptides comprising at least one drug-binding domain that non-covalently binds a drug. A polymeric carrier may be attached to an antibody specific for desired **target** cells to form immunoconjugates that deliver a drug to the **target** cells in vivo. The carriers are derived from drug binding proteins and produced through peptide synthesis or recombinant DNA technology.

L6 ANSWER 21 OF 21 USPATFULL
ACCESSION NUMBER: 93:70128 USPATFULL
TITLE: Delivery of x-ray contrast agents using receptor mediated endocytosis
INVENTOR(S): Jung, Chu, Arlington, MA, United States
Palmacci, Stephen, Walpole, MA, United States
Josephson, Lee, Arlington, MA, United States
PATENT ASSIGNEE(S): Advanced Magnetics, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5141739		19920825	
APPLICATION INFO.:	US 1991-679526		19910402 (7)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-384641, filed on 25 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-228640, filed on 4 Aug 1988, now abandoned which is a			

continuation-in-part of Ser. No. US 1987-73944, filed on 15 Jul 1987, now patented, Pat. No. US 4927945 which is a continuation-in-part of Ser. No. US 1986-882044, filed on 3 Jul 1986, now patented, Pat. No. US 4770183

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Raymond, Richard L.
ASSISTANT EXAMINER: Hollinden, Gary E.
LEGAL REPRESENTATIVE: Bromberg & Sunstein
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 662
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a method of **targeting** an x-ray contrast agent to a specific population of cells or organ. **Targeting** may be accomplished by forming a complex of a radiopaque label with a saccharide capable of interacting with a cell receptor. The resulting complex may then be internalized into the specific population of cells or organ by receptor mediated endocytosis. In one embodiment of the invention, the radiopaque label may include a compound containing iodine and the saccharide may include arabinogalactan, galactan, or derivatives thereof. The invention provides a method for determining the metabolic viability or disease state of the **target** cells or organ by visualizing the extent, mode of uptake and excretion of the **targeted** x-ray contrast agent by x-ray or computer tomography.

->